Abiopharma

🔍 HARRINGTON WILLIAM T (Director)

Company: Mobia Medical, Inc. (MOBI)

Report Date: 2026-01-30

Detailed Transactions and Holdings:

• Acquired 284,324 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 284,324.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 264,746 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 264,746.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 1,455,726 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 1,740,050.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Acquired 872,770 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | shares_owned_after: 1,137,516.00 | transaction_form_type: 4 | Footnotes: F4, F3
• Acquired 266,666 shares of Common Stock at $15.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 2,006,716.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 266,667 shares of Common Stock at $15.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,404,183.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 284,324 shares of Convertible Notes (Derivative)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,411,892.25 | transaction_form_type: 4 | Footnotes: F1, F5, F1, F1, F2
• Acquired 264,746 shares of Convertible Notes (Derivative)
  Date: 2026-01-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,176,955.03 | transaction_form_type: 4 | Footnotes: F3, F5, F1, F1, F3
• Acquired 31,520 shares of Stock Option at $15.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-07 | equity_swap_involved: 0 | shares_owned_after: 31,520.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 284,324 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 264,746 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F3
• Sold 1,128,438 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F2
• Sold 327,288 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F2
• Sold 872,770 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F3

Footnotes:

• F1: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
• F2: The securities are held by Osage University Partners III, LP ("OUP III"). Osage University GP III, LLC ("OUP III GP") is the general partner of OUP III. The Reporting Person is a manager of OUP III GP and may be deemed to share voting and dispositive power over the shares held by OUP III. Each of OUP III GP and the Reporting Person disclaims beneficial ownership over the securities held by OUP III, except to the extent of their pecuniary interests therein, if any.
• F3: The securities are held by Osage University Partners IV, LP ("OUP IV"). Osage University GP IV, LLC ("OUP IV GP") is the general partner of OUP IV. The Reporting Person is a manager of OUP IV GP and may be deemed to share voting and dispositive power over the shares held by OUP IV. Each of OUP IV GP and the Reporting Person disclaims beneficial ownership over the securities held by OUP IV, except to the extent of their pecuniary interests therein, if any.
• F4: Each share of the Series F Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Offering pursuant to its terms.
• F5: This transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended, in connection with the Offering, and is reported herein pursuant to Rule 16a-2(a).
• F6: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.